ALX Oncology Announces First Patients Dosed With Evorpacept and Sarclisa as Part of Randomized Phase 1/2 Umbrella Study With Sanofi
alx oncology宣佈,作爲賽諾菲安萬特1/2期隨機傘狀研究的一部分,首批患者接受了Evorpacept和Sarclisa的劑量。
ALX Oncology Announces First Patients Dosed With Evorpacept and Sarclisa as Part of Randomized Phase 1/2 Umbrella Study With Sanofi
alx oncology宣佈,作爲賽諾菲安萬特1/2期隨機傘狀研究的一部分,首批患者接受了Evorpacept和Sarclisa的劑量。
譯文內容由第三人軟體翻譯。